PMID- 37187501
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230517
IS  - 1927-1220 (Electronic)
IS  - 1927-1212 (Print)
IS  - 1927-1212 (Linking)
VI  - 12
IP  - 2
DP  - 2023 Apr
TI  - Incidence and Risk of Hematological Adverse Events Associated With Immune 
      Checkpoint Inhibitors: A Systematic Literature Review and Meta-Analysis.
PG  - 66-74
LID - 10.14740/jh1090 [doi]
AB  - BACKGROUND: Immune checkpoint inhibitors (ICIs) have been a breakthrough in 
      cancer therapy. ICI therapy is generally better tolerated than cytotoxic 
      chemotherapy; however, hematological adverse events (AEs) have not been fully 
      analyzed. Hence, we performed a meta-analysis to evaluate the incidence and risk 
      of ICI-related hematological AEs. METHODS: A systematic literature search was 
      performed using PubMed, EMBASE, Cochrane Library, and the Web of Science Core 
      Collection. Phase III randomized controlled trials (RCTs) involving ICI 
      combination regimens were selected. The experimental group received ICIs with 
      systemic treatment, and the control group received only the same systemic 
      treatment. Odds ratios (ORs) for anemia, neutropenia, and thrombocytopenia were 
      calculated using a random-model meta-analysis. RESULTS: We identified 29 RCTs 
      with 20,033 patients. The estimated incidence rates for anemia of all grades and 
      grades III-V were 36.5% (95% confidence interval (CI) 30.23 - 42.75) and 4.1% 
      (95% CI 3.85 - 4.42), respectively. The incidence of neutropenia (all grades 
      29.7%, grades III-V 5.3%) and thrombocytopenia (all grades 18.0%, grades III-V 
      1.6%) was also calculated. CONCLUSION: Treatment with ICIs seemed unlikely to 
      increase the incidence of anemia, neutropenia, and thrombocytopenia in all 
      grades. However, programmed cell death-1 receptor ligand inhibitors significantly 
      increased the risk of grades III-V thrombocytopenia (OR 1.53; 95% CI 1.11 - 
      2.11). Further research is needed to examine the potential risk factors.
CI  - Copyright 2023, Ohashi et al.
FAU - Ohashi, Takuma
AU  - Ohashi T
AD  - Department of Stem Cell and Immune Regulation, Yokohama City University Graduate 
      School of Medicine, Yokohama, Japan.
FAU - Takase-Minegishi, Kaoru
AU  - Takase-Minegishi K
AD  - Department of Stem Cell and Immune Regulation, Yokohama City University Graduate 
      School of Medicine, Yokohama, Japan.
FAU - Maeda, Ayaka
AU  - Maeda A
AD  - Department of Stem Cell and Immune Regulation, Yokohama City University Graduate 
      School of Medicine, Yokohama, Japan.
FAU - Hamada, Naoki
AU  - Hamada N
AD  - Department of Stem Cell and Immune Regulation, Yokohama City University Graduate 
      School of Medicine, Yokohama, Japan.
FAU - Yoshimi, Ryusuke
AU  - Yoshimi R
AD  - Department of Stem Cell and Immune Regulation, Yokohama City University Graduate 
      School of Medicine, Yokohama, Japan.
FAU - Kirino, Yohei
AU  - Kirino Y
AD  - Department of Stem Cell and Immune Regulation, Yokohama City University Graduate 
      School of Medicine, Yokohama, Japan.
FAU - Teranaka, Hiroshi
AU  - Teranaka H
AD  - Department of Stem Cell and Immune Regulation, Yokohama City University Graduate 
      School of Medicine, Yokohama, Japan.
FAU - Kunimoto, Hiroyoshi
AU  - Kunimoto H
AD  - Department of Stem Cell and Immune Regulation, Yokohama City University Graduate 
      School of Medicine, Yokohama, Japan.
FAU - Hagihara, Maki
AU  - Hagihara M
AD  - Department of Stem Cell and Immune Regulation, Yokohama City University Graduate 
      School of Medicine, Yokohama, Japan.
FAU - Matsumoto, Kenji
AU  - Matsumoto K
AD  - Department of Stem Cell and Immune Regulation, Yokohama City University Graduate 
      School of Medicine, Yokohama, Japan.
FAU - Namkoong, Ho
AU  - Namkoong H
AD  - Department of Infectious Diseases, Keio University School of Medicine, Tokyo, 
      Japan.
FAU - Horita, Nobuyuki
AU  - Horita N
AD  - Chemotherapy Center, Yokohama City University Hospital, Yokohama, Japan.
FAU - Nakajima, Hideaki
AU  - Nakajima H
AD  - Department of Stem Cell and Immune Regulation, Yokohama City University Graduate 
      School of Medicine, Yokohama, Japan.
LA  - eng
PT  - Journal Article
DEP - 20230430
PL  - Canada
TA  - J Hematol
JT  - Journal of hematology
JID - 101635099
PMC - PMC10181326
OTO - NOTNLM
OT  - Hematological toxicities
OT  - Immune checkpoint inhibitor
OT  - Immune-related adverse events
OT  - Meta-analysis
COIS- The authors declare that they have no conflict of interest.
EDAT- 2023/05/16 01:09
MHDA- 2023/05/16 01:10
PMCR- 2023/04/30
CRDT- 2023/05/15 19:26
PHST- 2023/02/06 00:00 [received]
PHST- 2023/03/25 00:00 [accepted]
PHST- 2023/05/16 01:10 [medline]
PHST- 2023/05/16 01:09 [pubmed]
PHST- 2023/05/15 19:26 [entrez]
PHST- 2023/04/30 00:00 [pmc-release]
AID - 10.14740/jh1090 [doi]
PST - ppublish
SO  - J Hematol. 2023 Apr;12(2):66-74. doi: 10.14740/jh1090. Epub 2023 Apr 30.